

THYROID FUNCTION TEST

SPECIMEN: Serum

Date 29/06/2022
Time 09:30am

		THYROID PEROXIDASE (TPO) ANTIBODIES (U/ml)
		Reference Range
Thyroid Stimulating Hormone:	3.54 mIU/L	0.50 - 4.00 mIU/L
Free Thyroxine (FT4):	14.2 pmol/L	9.0 - 25.0 pmol/L
Free Tri-iodothyronine (FT3):	5.5 pmol/L	3.5 - 6.5 pmol/L

Comments:

Thyroid Levels within range.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: RT3, TMA-R, FT-4, FT3, THA-R, TSH-R

ALL TESTS COMPLETE

DATE: 29/06/2022

THYROID ANTIBODIES

SPECIMEN: Serum

BIOCHEMISTRY - THYROID ANTIBODIES - CUMULATIVE

SPECIMEN: SERUM

DATE:

THYROGLOBULIN (TG)
ANTIBODIES (U/ml)

THYROID PEROXIDASE (TPO)
ANTIBODIES (U/ml)

29/06/2022

22 (< 60)

28 (< 60)

Normal thyroid antibodies.

*** Patient Copy ***

PATIENT: MARIA ROMANIN

PANEL CODES: RT3, TMA-R, FT-4, FT3, THA-R, TSH-R

ALL TESTS COMPLETE

Methylenetetrahydrofolate (MTHFR)

MOLECULAR BIOLOGY

SPECIMEN: BUCCAL SWAB

Methylenetetrahydrofolate (MTHFR)

MTHFR Gene Mutation (C677T) : Heterozygous for the mutation. Mutation detected.

MTHFR Gene Mutation (A1298C) : Not detected

Comment: This patient has one copy of the MTHFR C677T and is clear for the A1298C mutation.

Clinical notes: Methylenetetrahydrofolate reductase (MTHFR) is a regulatory enzyme in folate-dependent homocysteine remethylation. A mutation in the MTHFR gene may affect fertility in both sexes, mood disorders and mental health, autism spectrum disorders, risk of venous thrombosis, and is associated with elevated plasma homocysteine. A common polymorphism (mutation) in the MTHFR gene at position 677 is associated with a thermolabile enzyme with decreased activity. The associated prevalence of the homozygous mutation ranges from 8-18% in various populations. A second mutation (at position 1298) has been described and is associated with increased homocysteine levels when in association with the mutation position at position 677.

M
O
L
E
C
U
L
A
R
B
I
O
L
O
G
Y

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: MFF-R

ALL TESTS COMPLETE

SERUM 25 - HYDROXY VITAMIN D

BIOCHEMISTRY - SERUM 25 - HYDROXY VITAMIN D

SPECIMEN: SERUM

DATE:

Hydroxy - Vitamin D

Reference Range

29/06/2022

52 nmol/L

> 50

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: HXY-VD25

ALL TESTS COMPLETE

PROTEIN STUDIES - C REACTIVE PROTEIN

Date

Units

Reference Range

29/06/2022

9 mg/L*

<3 mg/L

Comments:

CRP levels above 10mg/L indicate high levels of inflammation.

Patient History: This patient has indicated a history of Endometriosis.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: CRP/S

ALL TESTS COMPLETE

IRON STUDIES

SPECIMEN: Serum

	Units	Reference Range
Ferritin :	57	15 - 165
Iron :	17 umol/L	7 - 27
Transferrin :	2.6 g/L	2.0 - 3.6
Transferrin Saturation :	20%	13 - 47 %

Comments:

Levels within range.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: IS

ALL TESTS COMPLETE

GLUCOSE STUDIES - FASTING

Glucose : 6.4mmol/L Reference (<140mg/dL)

BUN: 0.7mmol/L

K: 3.5mmol/L

Na: 137mmol/L

Creatinine:

Blood glucose levels within range.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: GSE

ALL TESTS COMPLETE

HOMOCYSTEINE

	Units	Reference Range
Homocysteine:	6.8umol/L	4.5 - 7.0umol/L

Comments:

Homocysteine levels within range.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: HOM

ALL TESTS COMPLETE

URINARY IODINE

SPECIMEN: URINE

	Units	Reference Range
Urinary Creatinine:	10.0 mmol/L	4.0 - 20.0
Urinary Iodine (Spot):	70 µg/L	>99

Comments:

INTERPRETIVE GUIDELINES:

<20 µg/L: Severe IDD
20 - 49 µg/L: Moderate IDD
50 - 99 µg/L: Mild IDD
>100 µg/L: No deficiency

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: IOS-R

ALL TESTS COMPLETE

FULL BLOOD EXAMINATION

	Units	Reference Range
HB:	129 g/L	115 - 165
PCV:	0.43 L/L	0.37 - 0.47
RCC:	4.66 x10 ¹² /L	3.80 - 5.80
MCV:	89 fL	80 - 99
MCH:	30 pg/mL	27 - 32
MCHC:	322 g/L	320 - 360
RDW:	15.7%	11.0 - 16.0
WHITE CELL COUNT:	8.9	4.0 - 11.0
Neutrophils:	3.5	2.0 - 8.0
Lymphocytes:	2.2	1.0 - 4.0
Monocytes:	0.4	0.0 - 0.1
Eosinophils:	0.3	0.0 - 0.5
Basophils	0.0	0.0 - 0.2
Platelets:	337	150 - 450

Comments:

Patient levels within range.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: FBC

ALL TESTS COMPLETE

INSULIN STUDIES - FASTING

Date	Time	Units	Reference range
------	------	-------	-----------------

29/06/2022	9:30am	8mU/L	2 - 12mU/L
------------	--------	-------	------------

Comments:

Patient levels within borderline range.

Total B12

Normal levels: > 180 pmol/L

Borderline: 150 - 180 pmol/L

Deficient: < 150 pmol/L

Folate (serum) B12

Normal levels: > 25 pmol/L

Borderline: 10 - 25 pmol/L

Comments:

Patient levels within range.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: INS

ALL TESTS COMPLETE

VITAMIN B12

	Units	Reference Range
Total B12 :	159 pmol/L	> 180 pmol/L
Holotranscobalamin (Active B12):	32 pmol/L	> 35 pmol/L

Comments:

Patient levels within borderline range.

Total B12

Normal Levels: > 180 pmol/L
Borderline: 150 - 180 pmol/L
Deficient: < 150 pmol/L

Holotranscobalamin

Normal Levels: > 35 pmol/L
Borderline: 30 - 35 pmol/L
Deficient: < 30 pmol/L

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: B12

ALL TESTS COMPLETE

LIPID STUDIES - FASTING

Total Chol:	7.2	mmol/L
Triglyceride:	1.2	mmol/L
HDL - C:	2.6	mmol/L
LDL - C:	3.0	mmol/L
NON HDL - C:	3.8	mmol/L
Chol/HDL Ratio:	2.5	

Therapeutic targets vary depending on the patient's cardiovascular risk profile.

	T. Chol	Trig	HDL-C	LDL-C	Non HDL-C
Primary Prevention	<4.0	<2.0	>=1.0	<2.0	<2.5
Secondary Prevention:		<2.0	>=1.0	<1.8	<2.5

National Vascular Disease Prevention Alliance Guidelines 2014.
<http://strokefoundation.com.au>

National Heart Foundation Guidelines 2012.
<http://www.heartfoundation.org.com.au>

Note: The Chol/HDL ratio reflects changes in VLDL, LDL and HDL, with high values indicating an increased risk of atherosclerosis.
Target values < 3.5 are sometimes recommended for people with known vascular disease or others at high risk.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: LIP

ALL TESTS COMPLETE

BLOOD HAEMOGLOBIN A 1c

Date	HbA1C %	HbA1c mmol/mol
29/06/2022	5.9	37

For diagnosis of diabetes mellitus the cut off is 6.5%.

For monitoring diabetic patients use the guidelines below.

Guidelines	HbA1c%	HbA1c mmol/mol
General Target	< 7.1	< 54
Adequate	< 8.1	< 65
Suboptimal	> 8.0.	> 64

Note: HbA1c reporting will move to mmol/mol units over the next 3 years.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: HBA1C

ALL TESTS COMPLETE

SERUM LACTATE DEHYDROGENASE

	Units	Reference Range
Lactase Dehydrogenase:	295	(240 - 480)

Comments:

Patient levels within range.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: LDH

ALL TESTS COMPLETE

ERYTHROCYTE SEDIMENTATION RATE (Blood)

ESR (Westergren) : 9 mm/hr (<20)

Comments:

Patient levels within range.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: ESR

ALL TESTS COMPLETE

ANTI-NUCLEAR ANTIBODIES

ANA
Titre, Pattern

* Detected
19:160

Comments on Lab Id: 341028405

Speckled patterns occur in SLE, mixed connective tissue disease, systemic Sjogren's syndrome and other connective tissue disorders. Suggest anti dsDNA antibodies and anti ENA antibodies on a new specimen if not already requested and clinically indicated.

*** Patient Copy ***

PATIENT: MARIA ROMANIN
PANEL CODES: ANA

ALL TESTS COMPLETE